Caris Life Sciences

Caris Life Sciences™ is a leading biosciences company specializing in the development and commercialization of the highest quality pathology services, molecular profiling, and blood-based diagnostic technologies, in the fields of oncology, dermatology, hematology, gastroenterology and urology.

The company provides academic-caliber consultations for thousands of patients a day, through its industry-leading team of expert, subspecialty pathologists. Caris also offers advanced molecular analyses of patient samples through prognostic testing services and genomic, transcriptomic, and proteomic profiling to assist physicians in their treatment of cancer. Currently, Caris is developing the Carisome™ platform, a proprietary, blood-based technology for diagnosis, prognosis, and theranosis of cancer and other complex diseases.

Caris is a privately-held leader in biosciences, headquartered in the Dallas-Fort Worth Metroplex, with U.S. operations in Phoenix, Arizona and Boston, Massachusetts and a globalization effort that has begun in Lausanne, Switzerland.

Subspecialty Expertise

dermatology

Dermatology

See why Caris’ dermatopathology service is growing with consultations on biopsies from 275,000 patients in 2009.

gastroenterology

Gastroenterology

Explore why Caris is the largest outpatient gastrointestinal pathology facility in the nation.

hematology

Hematology

Learn how Caris delivers the highest quality expertise in blood and bone marrow pathology.

urology

Urology

Discover how Caris’ urologic pathology experts focus on service and diagnostic excellence.

Chairman's Corner

Caris Cares
May 17 -
The American Healthcare System is broken!  Payors are put in a position to force their policy holders (patients) to access the cheapest healthcare provider possible and to deny care entirely whenever they can get away with it.  But it’s...
Chairman's Corner

Blood-Based Carisome™ Platform

Diagnostic, Prognostic, Predictive

Representing a revolution in blood-based diagnostics, prognostics and therapeutic guidance.

Caris Target Now

Molecular Profiling Series

Innovative tumor analysis that informs therapeutic guidance for oncology.

Pathology Services

Quality Diagnostics

Pathology subspecialists partnering to produce academic-caliber diagnoses.